| Identification | Back Directory | [Name]
4,5-DIHYDRO-N-[4-[[4-(1-METHYLETHOXY)PHENYL]METHYL]PHENYL]-1H-IMIDAZOL-2-AMINE | [CAS]
221529-58-4 | [Synonyms]
CAY10441
RO1138452
CAY10441 RO1138452
RO1138452 CAY10441
CAY10441 Exclusive
RO 1138452;RO-1138452;RO1138452;CAY 10441;CAY-10441;CAY10441
N-(4-(4-Isopropoxybenzyl)phenyl)-4,5-dihydro-1H-imidazol-2-amine
4,5-DIHYDRO-N-[4-[[4-(1-METHYLETHOXY)PHENYL]METHYL]PHENYL]-1H-IMIDAZOL-2-AMINE
1H-Imidazol-2-amine, 4,5-dihydro-N-[4-[[4-(1-methylethoxy)phenyl]methyl]phenyl]- | [Molecular Formula]
C19H23N3O | [MDL Number]
MFCD08062147 | [MOL File]
221529-58-4.mol | [Molecular Weight]
309.41 |
| Chemical Properties | Back Directory | [Boiling point ]
449.7±47.0 °C(Predicted) | [density ]
1.13±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
DMF: 30 mg/ml; DMF:PBS (pH 7.2)(1:10): 0.05 mg/ml; DMSO: 20 mg/ml; Ethanol: 20 mg/ml | [form ]
A crystalline solid | [pka]
9.94±0.33(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Uses]
RO1138452 is a potent and selective IP (prostacyclin) receptor antagonist. RO1138452 displays high affinity for IP receptors. In human platelets, pKi is 9.3±0.1; in a recombinant IP receptor system, pKi is 8.7±0.06. | [in vivo]
RO1138452 is a potent and selective antagonist for both human and rat IP receptors and that is possesses analgesic and anti-inflammatory potential. RO1138452 (1-10 mg/kg, i.v.) significantly reduces acetic acid-induced abdominal constrictions. RO1138452 (3-100 mg/kg, p.o.) significantly reduces carrageenan-induced mechanical hyperalgesia and edema formation. One hour after administration of RO1138452 (5 mg/kg, i.v.) to rats, the total plasma concentration is 0.189 μg/mL, whereas the free plasma concentrations is calculated to be 0.009 μg/mL (28 nM)[1]. | [IC 50]
Rat I2 Receptor: 7 nM (IC50); Rat I2 Receptor: 8.33 (pKi); Rabbit PAF Receptor: 52.9 nM (IC50); Human α2A adrenoceptor: 724 nM (IC50); Rat α1B adrenoceptor: 3280 nM (IC50); Human Muscarinic M4 Receptor: 1450 nM (IC50); Human muscarinic M2 Receptor: 2220 nM (IC50); Human muscarinic M1 Receptor: 2570 nM (IC50); Human muscarinic M5 Receptor: 3110 nM (IC50); Rat 5-HT1B Receptor: 1130 nM (IC50); pig 5-HT2C Receptor: 1190 nM (IC50); Rat 5-HT2A Receptor: 3040 nM (IC50); Human 5-HT1A Receptor: 8580 nM (IC50); Guinea-pig 5-HT4 Receptor: 8910 nM (IC50); Rat α1B adrenoceptor: 5.87 (pKi); Human α2A adrenoceptor: 6.49 (pKi); Human muscarinic M1 Receptor: 5.66 (pKi); Human muscarinic M5 Receptor: 5.81 (pKi); Human muscarinic M2 Receptor: 5.88 (pKi); Human muscarinic M4 Receptor: 6.14 (pKi); Rabbit PAF Receptor: 7.9 (pKi); Guinea-pig 5-HT4 Receptor: 5.35 (pKi); Human 5-HT1A Receptor: 5.37 (pKi); Rat 5-HT2A Receptor: 5.71 (pKi); Rat 5-HT1B Receptor: 6.11 (pKi); Pig 5-HT2C Receptor: 6.11 (pKi) | [References]
[1] Bley KR, et al. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol. 2006 Feb;147(3):335-45. DOI:10.1038/sj.bjp.0706554
[2] Ayer LM, et al. 4,5-Dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) is a selective, pseudo-irreversible orthosteric antagonist at the prostacyclin (IP)-receptor expressed by human airway epithelial cells: IP-receptor-mediated inhibition of CXCL9 and CXCL10 release. J Pharmacol Exp Ther. 2008 Feb;324(2):815-26. DOI:10.1124/jpet.107.129312 |
|
|